Skip to main content

Table 7 Non-orphan oncology drugs and indications.

From: Establishing a reasonable price for an orphan drug

Name

Indication

Lonsurf

To treat adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy

Kadcyla

To treat (adult) patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane

Xofigo

To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs

Inlyta

To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer

Perjeta

To treat patients with HER2-positive late-stage (metastatic) breast cancer in combination with Herceptin and docetaxel

Xtandi

To treat men with late-stage (metastatic) castration-resistant prostate cancer who have received docetaxel therapy

Zytiga

In combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy)